Company / SG&A Expense
vTv Therapeutics Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$11.9M
FY2025
5-year range
$7.3M / $12.3M
FY2021-FY2025
Trend
-2.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 10 years, ranging from $7M in FY2022 to $12M in FY2023.
Based on SEC 10-K filings.
$12M in FY2025 with a 5-year CAGR of +5.2%.
Improved from $12M to $12M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +18.0%
- 5-Year CAGR
- +5.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +5.2%, indicating consistent growth.
- In FY2025, sg&a expense decreased 2.4% year-over-year.
- Peak sg&a expense was recorded in FY2023.
- Lowest sg&a expense in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.9M | -2.4% |
| FY2024 | $12.2M | -1.2% |
| FY2023 | $12.3M | +70.2% |
| FY2022 | $7.3M | -15.1% |
| FY2021 | $8.5M | -7.4% |
| FY2020 | $9.2M | -18.6% |
| FY2019 | $11.3M | +14.4% |
| FY2018 | $9.9M | +9.1% |
| FY2017 | $9.1M | -22.5% |
| FY2016 | $11.7M | +3.0% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026